Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of SPN 812 ER 200 and 400 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

Trial Profile

Evaluation of SPN 812 ER 200 and 400 mg Efficacy and Safety in Adolescents With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2018 Primary endpoint has been met. (Efficacy of SPN-812 ER assessed by ADHD-RS-5 Rating Scale), according to a Supernus Pharmaceuticals media release.
    • 20 Dec 2018 Results presented in a Supernus Pharmaceuticals media release.
    • 06 Nov 2018 According to a Supernus Pharmaceuticals media release, data from this trial is expected by the end of December 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top